Alternative Name
PLCG2 Mutation Analysis
Methodology
Molecular
Test Description

Bi-directional sequencing to detect mutations in exons 19, 20, and 24, covering amino acid ranges W646 to S679, A681 to M743, and I839 to V860. Testing is available separately or in combination with the BTK Inhibitor Acquired Resistance Panel. NeoGenomics recommends ordering the combination Panel.

Clinical Significance

PLC-gamma-2 is immediately downstream of BTK in B-cell regulation pathways. Mutations in PLCG2 are associated with acquired or secondary resistance to ibrutinib arising after initial response in CLL.

Specimen Requirements

Peripheral blood: 5 mL in EDTA tube. Bone marrow: 2 mL in EDTA tube.
FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns.
Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.

Storage and Transportation

Use cold pack for transport. Make sure cold pack is not in direct contact with specimen.

CPT Code(s)*
81320 (effective July 2019) | Prior CPT Code was 81479 (before July 2019)
Turnaround Time

10 days

Level of Service
Global

*The CPT codes provided with our test descriptions are based on AMA guidelines and are for informational purposes only. Correct CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payor being billed.